Overview
AVLN market data
Price History
AVLN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.04 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $24.15 – $33.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.3K.
Company news
8-K filing — Avalyn Pharma Inc. (AVLN)SEC EDGAR · Jul 1, 2026, 9:20 PM
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary FibrosisGlobenewswire Inc · Jun 17, 2026, 12:15 PM
Avalyn Completes Target Enrollment In Phase 2b MIST Trial Of AP01Benzinga · Jun 17, 2026, 12:10 PM
Avalyn Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobenewswire Inc · Jun 3, 2026, 11:15 AM
This Lear Analyst Turns Bullish; Here Are Top 4 Upgrades For TuesdayBenzinga · May 26, 2026, 4:12 PM
Evercore ISI Group Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $51Benzinga · May 26, 2026, 2:45 PM
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · May 26, 2026, 12:56 PM
Guggenheim Initiates Coverage On Avalyn Pharma with Buy Rating, Announces Price Target of $80Benzinga · May 26, 2026, 12:46 PM
Morgan Stanley Initiates Coverage On Avalyn Pharma with Overweight Rating, Announces Price Target of $53Benzinga · May 26, 2026, 11:34 AM
Avalyn Pharma To Present Updated Findings From ATLAS Open-Label Extension Trial Highlighting Long-Term Tolerability Profile Of AP01 For Treatment Of Pulmonary Fibrosis, At EULAR 2026Benzinga · May 21, 2026, 12:10 PM